Jon Stevenson

Fluidform LLC is a company that specializes in 3D bioprinting technology for regenerative medicine and tissue engineering. The company is based in Sudbury, MA. The company's patented fresh 3D printing technology is the most advanced biofabrication platform in the world, as published in Science. The company's robust pipeline includes development and preclinical programs addressing significant unmet need in human health, such as bioprosthetic implantable medical devices and a new generation of structurally and compositionally complex tissue models to test drug efficacy and cardiotoxicity, with an ultimate focus on tissue and organ replacement. Fluidform was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO since 2018.

Fluidform LLC is a company that specializes in 3D bioprinting technology for regenerative medicine and tissue engineering. The company is based in Sudbury, MA. The company's patented fresh 3D printing technology is the most advanced biofabrication platform in the world, as published in Science. The company's robust pipeline includes development and preclinical programs addressing significant unmet need in human health, such as bioprosthetic implantable medical devices and a new generation of structurally and compositionally complex tissue models to test drug efficacy and cardiotoxicity, with an ultimate focus on tissue and organ replacement. Fluidform was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO since 2018.

Fluidform LLC is a company that specializes in 3D bioprinting technology for regenerative medicine and tissue engineering. The company is based in Sudbury, MA. The company's patented fresh 3D printing technology is the most advanced biofabrication platform in the world, as published in Science. The company's robust pipeline includes development and preclinical programs addressing significant unmet need in human health, such as bioprosthetic implantable medical devices and a new generation of structurally and compositionally complex tissue models to test drug efficacy and cardiotoxicity, with an ultimate focus on tissue and organ replacement. Fluidform was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO since 2018.

Fluidform LLC is a company that specializes in 3D bioprinting technology for regenerative medicine and tissue engineering. The company is based in Sudbury, MA. The company's patented fresh 3D printing technology is the most advanced biofabrication platform in the world, as published in Science. The company's robust pipeline includes development and preclinical programs addressing significant unmet need in human health, such as bioprosthetic implantable medical devices and a new generation of structurally and compositionally complex tissue models to test drug efficacy and cardiotoxicity, with an ultimate focus on tissue and organ replacement. Fluidform was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO since 2018.

Fluidform LLC is a company that specializes in 3D bioprinting technology for regenerative medicine and tissue engineering. The company is based in Sudbury, MA. The company's patented fresh 3D printing technology is the most advanced biofabrication platform in the world, as published in Science. The company's robust pipeline includes development and preclinical programs addressing significant unmet need in human health, such as bioprosthetic implantable medical devices and a new generation of structurally and compositionally complex tissue models to test drug efficacy and cardiotoxicity, with an ultimate focus on tissue and organ replacement. Fluidform was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO since 2018.